Comparative Pharmacology
Head-to-head clinical analysis: POLMON versus XTRELUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLMON versus XTRELUS.
POLMON vs XTRELUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
Selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and lowering blood glucose levels.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
XTRELUS (luseogliflozin) 2.5 mg orally once daily, increased to 5 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
The terminal elimination half-life is approximately 12 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life is prolonged to 20-24 hours, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Renal excretion accounts for approximately 65% of the administered dose as unchanged drug, with an additional 20% as metabolites. Biliary/fecal excretion accounts for the remaining 15%, primarily as metabolites.
Category C
Category C
Bronchodilator
Bronchodilator